Home/ In Focus
ESID's important announcements, news, articles...
Joint statement on the current epidemics of new Coronavirus
Together with IPOPI, INGID, APSID, ASID, ARAPID, CIS, LASID, SEAPID we have worked on a joint statement to provide guidance in advising patients with primary immunodeficiency under our care in the current COVID-19 context.
IPOPI – ESID Joint Statement: The use of monoclonal antibody treatment for patients with PID in the context of the COVID-19 pandemicIPOPI ESID Statement IPOPI – ESID Joint Statement The use of monoclonal antibody treatment for patients with PID in the context of the COVID-19 pandemic 11 November 2021 The role of monoclonal antibody (mAb or moAb) therapies in the treatme...
ESID COVID-19 Statement, March 2022
Since the start of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, there has been rapid progress with understanding disease, clinical phenotypes and biology, improving treatment and implementing vaccination trials. Data is accumulating about the impact of COVID-19 for patients with Inborn Errors of Immunity (IEI). The purpose of this statement is to summarise our state of knowledge and set out ESID’s current guidance for professionals in the IEI community in Europe. We will update this statement as evidence emerges.